• 1st Feb 2021. Biotherapy Services Ltd Launches the Second Institutional Funding Round
  • December 2020 Pan European Patent Granted for the RAPID™ Biodynamic Haematogel
  • EWMA poster published November 2020
  • November 2020 – Care Quality Commission (CQC) accreditation.
  • March 2020 MHRA requested suspension of all non-COVID-19 clinical trial sites. BTS has focused on validation and expansion of new trial sites for reopening Quarter 1 2021. New sites in Loughborough and Bradford are scheduled to open in the 1st Quarter 2021
  • March 2019 Commencement of Rapid DFU-1 NIHR Clinical Trial at The Royal London Barts Health NHS Trust.
  • November 2019 Closure of First Institutional funding round with investment of £3 million by Foresight Group a leading independent infrastructure and private equity investment manager.
  • August 2018 the Company was granted a MIA/(IMP) Licence by the MHRA to manufacture the RAPID™ Biodynamic Haematogel wound care treatment for clinical trial patients.
  • April 2021 the Company was awarded the innovative medicine designation – the Innovation Passport – for RAPIDTM Biodynamic Haematogel in the treatment of chronic ulceration of the diabetic foot. The Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP), a new UK approval process designed to reduce time to market and accelerate access to innovative medicines.

Investment Opportunity

Biotherapy Services Ltd is a private limited company approved under the UK Enterprise Investment Scheme (EIS). There is now an opportunity to join our current shareholder list by equity investment into the company. For more information, please contact Biotherapy Services Ltd by email at


Request Investor Information

There is now a unique opportunity to join our current shareholder list by equity investment into the company.

For further information about becoming an investor, please email